Sign in
CompletedNo phase

Clinical Study Evaluating the Efficacy and Safety of Colchicine in Adult Patients With Sepsis

Key facts

Who runs it
Tanta University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
46 people enrolled
Started
1 Nov 2023
Ended
30 Aug 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • conventional sepsis therapy alone
  • colchicine 500 mcg oral twice daily plus conventional sepsis therapy.
Record updated
23 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Other criteria

  • Inclusion criteria:; Adult age ≥18 years old; Both male and female sex; Patients diagnosed with sepsis regardless its etiology according to the definitions of SSC
  • Exclusion criteria:; Late septic shock at presentation with multiple organ failure; Serious gastrointestinal disease; Preexisting end stage liver disease; Preexisting end stage renal disease; Pregnancy and breast-feeding women; History of allergy or intolerance to Colchicine; Patient with malignancies; Uncontrolled hemorrhage; Burn; Patients on immunosuppressant or biological therapies; Concomitant use of P-glycoprotein (P-gp) inhibitor such as: Verapamil, and Amiodarone or strong CYP3A4 inhibitor such as: Clarithromycin, Ritonavir and Ketoconazole

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Inflammatory markers are found to be an important contributor in sepsis. We evaluate the effect of colchicine on inflammatory processes and its possible protective effect against oxidative stress and organ dysfunction in adult patients suffering from sepsis.

The 2 groups in the trial

  • Group 1 (Control group)Placebo, for comparison

    Treatment: conventional sepsis therapy alone

  • Group 2 (Colchicine group)Existing treatment, for comparison

    Treatment: colchicine 500 mcg oral twice daily plus conventional sepsis therapy.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Study Evaluating the Efficacy and Safety of Colchicine in Adult Patients With Sepsis.
Record updated
23 July 2025